Actinogen Medical (ASX:ACW) EBITDA Margin %: 0.00% (As of Dec. 2025)

What is Actinogen Medical EBITDA Margin %?

Actinogen Medical ASX:ACW +1.52% EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Actinogen Medical ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Actinogen Medical's EBITDA for the six months ended in Dec. 2025 was A$-10.98 Mil. Actinogen Medical's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Actinogen Medical's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Actinogen Medical (ASX:ACW) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Actinogen Medical EBITDA Margin % Related Terms

Actinogen Medical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Actinogen Medical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actinogen Medical EBITDA Margin % Chart

Actinogen Medical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

EBITDA Margin %

Get a 7-Day Free Trial

0.00

Actinogen Medical Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

ASX:ACW vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Actinogen Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actinogen Medical EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's EBITDA Margin % falls into.

Save Embed

Actinogen Medical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Actinogen Medical's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2025 )	/	Revenue (A: Jun. 2025 )
	=	-14.261	/	0
	=	%

Actinogen Medical's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	-10.984	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Actinogen Medical (ASX:ACW) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Actinogen Medical and its competitors. According to the industry distribution chart, Actinogen Medical ranks #999999 out of 945 companies in the Biotechnology industry.

Is Actinogen Medical's EBITDA Margin % too high?

Actinogen Medical's current EBITDA Margin % is 0.00%. Based on the distribution chart, Actinogen Medical ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.

How does Actinogen Medical's EBITDA Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Actinogen Medical ranks #999999 out of 945 companies for EBITDA Margin %. This places Actinogen Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Actinogen Medical and its competitors. Actinogen Medical's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Actinogen Medical stock overvalued right now?

Actinogen Medical (ASX:ACW) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Actinogen Medical (ASX:ACW), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinogen Medical Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:NYR ASX:RCE ASX:ILA ASX:DXB ASX:ATH ASX:PAR ASX:ALA ASX:PTX ASX:IMM ASX:ATX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ATGGF:USA 3AC:Germany

Address 109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000

Website https://www.actinogen.com.au

Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.